PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
8.54%
Cost increase while AGEN reduces costs. John Neff would investigate competitive disadvantage.
-83.05%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-18.94%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
28.45%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-7.93%
Both companies reducing total costs. Martin Whitman would check industry trends.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
8.54%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
7.52%
EBITDA growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
7.21%
Operating income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-9.03%
Other expenses reduction while AGEN shows 31.11% growth. Joel Greenblatt would examine advantage.
7.01%
Pre-tax income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-68.42%
Tax expense reduction while AGEN shows 31.59% growth. Joel Greenblatt would examine advantage.
7.01%
Net income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
8.82%
EPS growth while AGEN declines. John Neff would investigate advantages.
8.82%
Diluted EPS growth while AGEN declines. John Neff would investigate advantages.
0.91%
Share count reduction exceeding 1.5x AGEN's 9.00%. David Dodd would verify capital allocation.
0.91%
Diluted share reduction exceeding 1.5x AGEN's 9.00%. David Dodd would verify capital allocation.